BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:AZD9550 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of AZD9550\, from ClinicalTrials.gov estimat
 es.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06151964-150@assetmemo.bio
DTSTAMP:20261121T004547Z
DTSTART;VALUE=DATE:20270129
DTEND;VALUE=DATE:20270130
SUMMARY:AZD9550: Phase 1/2 readout est. (NCT06151964)
DESCRIPTION:AZD9550\, phase 1/2\, Obesity.\nStudy: A Trial to Learn How Saf
 e AZD9550 Monotherapy and Combined With AZD6234 is in People With or Witho
 ut Type 2 Diabetes Who Are Living With Obesity and Overweight\nEstimated p
 rimary completion: 29 January 2027. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/azd9550#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT06151964
URL:https://assetmemo.bio/drug/azd9550#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07546760-150@assetmemo.bio
DTSTAMP:20261121T004547Z
DTSTART;VALUE=DATE:20270204
DTEND;VALUE=DATE:20270205
SUMMARY:AZD9550: Phase 1 readout est. (NCT07546760)
DESCRIPTION:AZD9550\, phase 1.\nStudy: A Phase I Study to Investigate the E
 ffect of Hepatic Impairment of AZD9550 and AZD6234\nEstimated primary comp
 letion: 4 February 2027. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/azd9550#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07546760
URL:https://assetmemo.bio/drug/azd9550#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07911514-150@assetmemo.bio
DTSTAMP:20261121T004547Z
DTSTART;VALUE=DATE:20270504
DTEND;VALUE=DATE:20270505
SUMMARY:AZD9550: Phase 1 readout est. (NCT07911514)
DESCRIPTION:AZD9550\, phase 1.\nStudy: A Trial to Assess the Relative Bioav
 ailability of Different Subcutaneous Formulations of AZD9550 and AZD6234\n
 Estimated primary completion: 4 May 2027. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/azd9550#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT07911514
URL:https://assetmemo.bio/drug/azd9550#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07013643-150@assetmemo.bio
DTSTAMP:20261121T004547Z
DTSTART;VALUE=DATE:20270709
DTEND;VALUE=DATE:20270710
SUMMARY:AZD9550: Phase 1 readout est. (NCT07013643)
DESCRIPTION:AZD9550\, phase 1\, Obesity.\nStudy: A Study to Investigate the
  Effect of AZD6234\, AZD9550\, and a Combination of AZD9550 and AZD6234 on
  Pharmacokinetics of Combined Oral Contraceptive Ethinyl Estradiol/Levonor
 gestrel in Healthy Female Participants Living With Overweight or Obesity\n
 Estimated primary completion: 9 July 2027. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/azd9550#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT07013643
URL:https://assetmemo.bio/drug/azd9550#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
